Press release
Asthma Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | 90+ Companies are working to improve the Treatment of Space | Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, EMS, AstraZeneca, Inmunotek, Pearl Therape
Asthma Pipeline
In the Asthma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Asthma NDA approvals (if any), and product development activities comprising the technology, Asthma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from Asthma Pipeline Insight Report
• DelveInsight's Asthma Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Asthma.
• The leading Asthma Companies include Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, EMS, AstraZeneca, Inmunotek, Pearl Therapeutics Inc., Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, EURRUS Biotech, T-Balance Therapeutics, Teva Pharmaceutical Industries, Theravance Biopharma, Akeso Biopharma, Aldeyra Therapeutics, Gossamer Bio, Trio Medicines, Janssen Research & Development, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tethererx Pharmaceuticals, Genentech, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Knopp Biosciences, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, Chiesi Farmaceutici S.p.A., Aquilon Pharma, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, and others
• Promising Asthma Pipeline therapies include A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others.
• On June 2023, AstraZeneca announced a study of phase 3 clinical trials for Tezepelumab. A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma.
• On June 2023, Glenmark Pharmaceuticals Ltd India announced a study of phase 2 clinical trials for Revamilast.The primary objective of the study is to evaluate the effect of revamilast on lung function as assessed by Forced Expiratory Volume in one second (FEV1) after the therapy (12 weeks). Secondary objective includes area under curve for FEV1, Change in asthma symptoms, patient / investigator's global assessments and safety. Patients will be followed for safety and efficacy assessment at week 1, 4, 8 12 and 14 after start of therapy.
• On May 2023, GlaxoSmithKline announced a study of phase 3 clinical trials for GSK3511294 (Depemokimab). This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype.
To explore more information on the latest breakthroughs in the Asthma Pipeline treatment landscape of the report, click here @ Asthma Pipeline Outlook- https://www.delveinsight.com/report-store/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Asthma Overview
Asthma is a chronic disease that affects the airways. Asthma is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen.
For further information, refer to the detailed Asthma Unmet Needs, Asthma Market Drivers, and Asthma Market Barriers, click here for Asthma Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Asthma Emerging Drugs Profile
• PT-027: Avillion LLP
• MM09-MG01: Inmunotek S.L.
• FP 025: Foresee Pharmaceuticals
• GB001: Gossamer Bio
• EDP1867: Evelo Biosciences, Inc.
• TQC2731: Chia Tai Tianqing Pharmaceutical Group
Asthma Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Asthma. The companies which have their Asthma drug candidates in the most advanced stage, i.e. phase III include, Avillion LLP.
Request a sample and discover the recent advances in Asthma Ongoing Clinical Trial Analysis and Medications, click here @ Asthma Treatment Landscape- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Asthma Pipeline Report
• Coverage- Global
• Asthma Companies- Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, EMS, AstraZeneca, Inmunotek, Pearl Therapeutics Inc., Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, EURRUS Biotech, T-Balance Therapeutics, Teva Pharmaceutical Industries, Theravance Biopharma, Akeso Biopharma, Aldeyra Therapeutics, Gossamer Bio, Trio Medicines, Janssen Research & Development, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Genentech, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Knopp Biosciences, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, Chiesi Farmaceutici S.p.A., Aquilon Pharma, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, and others
• Asthma Pipeline therapies- A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others
• Asthma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Dive deep into rich insights for drugs for Asthma Market Drivers and Asthma Market Barriers, click here @ Asthma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Asthma Executive Summary
3. Asthma: Overview
4. Asthma Pipeline Therapeutics
5. Asthma Pipeline Therapeutic Assessment
6. Asthma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. PT-027: Avillion LLP
9. Mid Stage Products (Phase II/III)
10. PT001: Pearl Therapeutics (AstraZeneca)
11. Mid Stage Products (Phase II)
12. FP 025: Foresee Pharmaceuticals
13. Early Stage Products (Phase I/II)
14. AQ-001S: Aquilon Pharmaceuticals S.A
15. Early Stage Products (Phase I)
16. Itolizumab (EQ001): Equillium
17. Preclinical and Discovery Stage Products
18. KBP7026: KBP Biosciences
19. Inactive Products
20. Asthma Key Companies
21. Asthma Key Products
22. Asthma- Unmet Needs
23. Asthma- Market Drivers and Barriers
24. Asthma- Future Perspectives and Conclusion
25. Asthma Analyst Views
26. Asthma Key Companies
27. Appendix
Got Queries? Find out the related information on Asthma Mergers and acquisitions, Asthma Licensing Activities @ Asthma Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Asthma Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | 90+ Companies are working to improve the Treatment of Space | Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, EMS, AstraZeneca, Inmunotek, Pearl Therape here
News-ID: 3119958 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Asthma
Evolving Market Trends In The Asthma Spacers Industry: Smart Inhaler Devices Rev …
The Asthma Spacers Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Asthma Spacers Market Size During the Forecast Period?
The asthma spacers market has grown steadily, forecasted to rise from $1.88 billion in 2024 to $2.01 billion in 2025 at a CAGR…
Asthma Relief Reimagined: Trends Driving Asthma Spacer Innovation
The Business Research Company recently released a comprehensive report on the Global Asthma Spacers Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free…
Asthma Warning Sensors Market Connected Care for Asthma: How Warning Sensors Imp …
Asthma Warning Sensors Market Market to Record an Exponential CAGR by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Asthma Warning Sensors Market Size, Share & Trends Analysis Report By Type (Wearable v/s Non-Wearable), By Technology (AI, IoT, Machine Learning, Others), By Parameter Measured (FEV1 v/s Peak Flow), By End User (Hospitals & Clinics v/s Homecare)- Market…
Asthma Spacers Market Optimizing Asthma Treatment: How Spacers are Improving Del …
Asthma Spacers Market Assessment worth $ 2.47 Billion by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Asthma Spacers Market- by Product (Space Chamber Plus, A2A Spacer, Flo-Tone CR, Able Spacer, AeroChamber, Volumatic, Vortex, OptiChamber), Application (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get a free sample copy of…
Severe Asthma Treatment Market - Revitalizing Quality of Life: Severe Asthma Tre …
Newark, New Castle, USA: The "Severe Asthma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Asthma Treatment Market: https://www.growthplusreports.com/report/severe-asthma-treatment-market/8939
This latest report researches the industry structure,…
Asthma Monitoring Devices Market - Revolutionizing Asthma Care: Elevate Monitori …
Newark, New Castle, USA: The "Asthma Monitoring Devices Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Asthma Monitoring Devices Market: https://www.growthplusreports.com/report/asthma-monitoring-devices-market/8697
This latest report researches the industry structure,…
